More Than Window Dressing: Ornskov Seen As Key Asset In AbbVie’s Buyout Of Shire
Executive Summary
The Shire CEO will oversee integration of his company into AbbVie and head a focused rare-disease unit in the new company, but longer-term might be in position to succeed AbbVie CEO Gonzalez. AbbVie may look to Sanofi’s acquisition of Genzyme for a template on how to merge a rare diseases specialty play into big pharma.